Certolizumab pegol in the treatment of Crohn's disease

Author： Ferrante Marc   Vermeire Séverine   Rutgeerts Paul  

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.13, Iss.4, 2013-04, pp. : 595-605

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis

By Fleischmann Roy  

Expert Opinion on Biological Therapy, Vol. 10, Iss. 5, 2010-05 ,pp. : 773-786

Informa Healthcare

Access to resources Recommend Favorite

Certolizumab pegol in rheumatoid arthritis: current update

By Fechtenbaum Marie   Md Yusof Md Yuzaiful   Emery Paul  

Expert Opinion on Biological Therapy, Vol. 14, Iss. 6, 2014-06 ,pp. : 841-850

Informa Healthcare

Access to resources Recommend Favorite

Biological response modifiers for the treatment of Crohn’s disease

By Siveke J   Folwaczny C  

Expert Opinion on Biological Therapy, Vol. 4, Iss. 11, 2004-11 ,pp. : 1719-1727

Informa Healthcare

Access to resources Recommend Favorite

Teduglutide in Crohn's disease

By Blonski Wojciech  

Expert Opinion on Biological Therapy, Vol. 13, Iss. 8, 2013-12 ,pp. : 1207-1214

Informa Healthcare

Access to resources Recommend Favorite

Vedolizumab for Crohn's disease

By Mosli Mahmoud H   Feagan Brian G  

Expert Opinion on Biological Therapy, Vol. 13, Iss. 3, 2013-03 ,pp. : 455-463

Informa Healthcare

Access to resources Recommend Favorite